Opportunity Information: Apply for RFA DA 12 010
Apply for RFA DA 12 010
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "2012 NIDA Translational Avant Garde Award for Medication Development for the Treatment of Substance Use Disorders (DP1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Jul 29, 2011 and posted on Jul 29, 2011.
- Applicants must submit their applications by Feb 21, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- Eligible applicants include: Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) County governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities State governments For profit organizations other than small businesses Special district governments Private institutions of higher education Small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The 2012 NIDA Translational Avant Garde Award for Medication Development for the Treatment of Substance Use Disorders (DP1) (Funding Opportunity Number RFA-DA-12-010) is a National Institutes of Health grant program from the National Institute on Drug Abuse (NIDA) aimed at accelerating the translation of research into real-world medications for substance use disorders. The core idea is to back highly capable basic and/or clinical researchers who have the skills and momentum to move beyond discovery science and push promising concepts toward treatment-ready products. Rather than focusing only on understanding addiction mechanisms, this opportunity is centered on getting to interventions that can be tested and ultimately used to help patients.
The scientific scope is broad but clearly targeted: NIDA is seeking medication development efforts for substance use disorders related to tobacco, cannabis, cocaine, methamphetamine, heroin, and prescription opioids. Proposed therapeutics can be traditional small-molecule drugs or biologics. In this announcement, biologics explicitly include approaches such as vaccines and recombinant therapeutic proteins produced through biological processes. Applicants are allowed to focus either on treating the overall disorder (abuse or dependence) or on specific clinical features that commonly drive continued use and treatment failure, including withdrawal symptoms, craving, and relapse prevention. Importantly, the program is not limited to brand-new chemical entities; projects that develop new formulations of already marketed drugs (originally approved for other indications) or new combinations of existing medications are also considered within scope if they credibly address substance use disorders.
From an administrative and funding standpoint, this is a discretionary grant opportunity under the NIH DP1 mechanism, categorized under Education and Health, and aligned with CFDA 93.279 (Drug Abuse and Addiction Research Programs). The posting and creation date were July 29, 2011, with an application closing date of February 21, 2012, and an archive date of March 23, 2012. NIDA listed an estimated total funding amount of $3,000,000 for the opportunity, with an award ceiling of $1,000,000. The announcement specifies no cost sharing or matching requirement, which means applicants are not required to contribute non-federal funds as a condition of receiving the award.
Eligibility is intentionally expansive and includes a wide range of domestic and international organizations. Eligible applicants include public and private institutions of higher education, nonprofits with or without 501(c)(3) status, state and local governments (including counties, cities or townships, special district governments, and independent school districts), public housing authorities/Indian housing authorities, and for-profit organizations other than small businesses as well as small businesses. The FOA also highlights inclusion of organizations and institutions that serve specific communities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations. In addition, non-U.S. entities (foreign institutions) are eligible to apply, and non-U.S. components of U.S. organizations are also eligible, signaling that NIDA was open to strong medication development proposals regardless of geography as long as they fit NIH rules.
Overall, this funding opportunity is best understood as an acceleration program for medication development in addiction, meant to empower individual investigators or teams with the capability to bridge the gap from laboratory or clinical insight to tangible therapeutic candidates. The emphasis on both small molecules and biologics, as well as repurposing and combination strategies, reflects a pragmatic approach: NIDA was looking for credible, translationally grounded paths that could produce safe and effective treatments addressing not only substance use itself but also the clinical drivers of ongoing addiction like craving, withdrawal, and relapse.
For reference, the full announcement was posted by NIH at http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-12-010.html, and NIH Office of Extramural Research support contacts were provided for access or linking issues (FBOWebmaster@OD.NIH.GOV).
FAQs: 2012 NIDA Translational Avant Garde Award for Medication Development for the Treatment of Substance Use Disorders (DP1) (RFA-DA-12-010)
What is this funding opportunity?
This is a National Institutes of Health (NIH) grant program from the National Institute on Drug Abuse (NIDA) called the 2012 NIDA Translational Avant Garde Award for Medication Development for the Treatment of Substance Use Disorders, using the DP1 mechanism (Funding Opportunity Number RFA-DA-12-010).
What is the main goal of the program?
The program is intended to accelerate translation of research into real-world medications for substance use disorders. It is focused on pushing promising concepts beyond discovery science toward treatment-ready products that can be tested and ultimately used to help patients.
Is this opportunity focused on basic research or on product development?
It is centered on medication development and translation to interventions, rather than focusing only on understanding addiction mechanisms. The intent is to support researchers who can move promising concepts toward tangible therapeutic candidates.
Which NIH institute is sponsoring this opportunity?
The sponsoring NIH institute is the National Institute on Drug Abuse (NIDA).
What is the funding opportunity number?
The funding opportunity number is RFA-DA-12-010.
What grant mechanism is used for this program?
This opportunity uses the NIH DP1 mechanism.
What substance use disorders are in scope?
NIDA is seeking medication development efforts addressing substance use disorders related to tobacco, cannabis, cocaine, methamphetamine, heroin, and prescription opioids.
What types of therapeutics can be proposed?
Proposed therapeutics can include traditional small-molecule drugs or biologics.
What does "biologics" mean in this announcement?
In this announcement, biologics explicitly include approaches such as vaccines and recombinant therapeutic proteins produced through biological processes.
Do projects have to target the entire substance use disorder?
No. Applicants may focus either on treating the overall disorder (abuse or dependence) or on specific clinical features that commonly drive continued use and treatment failure.
Which specific clinical features are mentioned as acceptable targets?
The announcement specifically mentions withdrawal symptoms, craving, and relapse prevention as clinical features within scope.
Are only brand-new drug candidates eligible?
No. The program is not limited to brand-new chemical entities. Projects developing new formulations of already marketed drugs (originally approved for other indications) or new combinations of existing medications are also considered within scope if they credibly address substance use disorders.
What general category is this opportunity listed under?
It is described as a discretionary grant opportunity under NIH, categorized under Education and Health.
What CFDA program is associated with this opportunity?
This opportunity is aligned with CFDA 93.279 (Drug Abuse and Addiction Research Programs).
When was this opportunity posted?
The posting and creation date was July 29, 2011.
What was the application closing date?
The application closing date was February 21, 2012.
When was the opportunity archived?
The archive date was March 23, 2012.
How much total funding was estimated for this opportunity?
NIDA listed an estimated total funding amount of $3,000,000.
What is the award ceiling for a single award?
The award ceiling listed for this opportunity is $1,000,000.
Is cost sharing or matching required?
No. The announcement specifies no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of receiving the award.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include public and private institutions of higher education, nonprofits with or without 501(c)(3) status, state and local governments (including counties, cities or townships, special district governments, and independent school districts), public housing authorities/Indian housing authorities, and for-profit organizations (including small businesses and for-profit organizations other than small businesses).
Are community-serving institutions and organizations explicitly included?
Yes. The FOA highlights inclusion of organizations and institutions that serve specific communities, including Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. Non-U.S. entities (foreign institutions) are eligible to apply.
Can a U.S. organization include non-U.S. components in the application?
Yes. Non-U.S. components of U.S. organizations are also eligible, indicating openness to strong medication development proposals regardless of geography (as long as they fit NIH rules).
What kind of applicant is this program trying to support?
The program is described as backing highly capable basic and/or clinical researchers who have the skills and momentum to move beyond discovery science and push promising concepts toward treatment-ready products.
Where can I find the full announcement?
The full announcement was posted by NIH at http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-12-010.html.
Who is listed as a support contact for access or linking issues?
The NIH Office of Extramural Research support contact provided for access or linking issues is FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Education Health
Next opportunity: Pre Application for the 2012 NIDA Translational Avant Garde Award for Medication Development for the Treatment of Substance Use Disorders (X02)
Previous opportunity: Native American Student Support
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 12 010
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 12 010) also looked into and applied for these:
| Funding Opportunity |
|---|
| Pre Application for the 2012 NIDA Translational Avant Garde Award for Medication Development for the Treatment of Substance Use Disorders (X02) Apply for PAR 11 269 Funding Number: PAR 11 269 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pre Application for the FY12 NIDA Avant Garde Award Program for HIV/AIDS Research (X02) Apply for PAR 11 256 Funding Number: PAR 11 256 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| FY12 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 12 011 Funding Number: RFA DA 12 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Centers of Biomedical Research Excellence (COBRE) (P20) Apply for PAR 11 286 Funding Number: PAR 11 286 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Pilot studies in Pancreatic Cancer (R21) Apply for PA 11 297 Funding Number: PA 11 297 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Pilot studies in Pancreatic Cancer (R03) Apply for PA 11 298 Funding Number: PA 11 298 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Drug Abuse Prevention Intervention Research (R03) Apply for PA 11 313 Funding Number: PA 11 313 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Drug Abuse Prevention Intervention Research (R01) Apply for PA 11 311 Funding Number: PA 11 311 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Prevention Intervention Research (R21) Apply for PA 11 312 Funding Number: PA 11 312 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Human Health and Heredity in Africa (H3Africa) Research Grants (U01) Apply for RFA RM 11 009 Funding Number: RFA RM 11 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Scalable Assays for Unbiased In Vitro Analysis of Neurobiological Function (R21/R33) Apply for PAR 11 319 Funding Number: PAR 11 319 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions (R21) Apply for RFA CA 11 012 Funding Number: RFA CA 11 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions (R01) Apply for RFA CA 11 011 Funding Number: RFA CA 11 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| mHealth Tools to Promote Effective PatientProvider Communication, Adherence to Treatment and Self Management of Chronic Diseases In Underserved Populations (R03) Apply for PA 11 331 Funding Number: PA 11 331 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| mHealth Tools to Promote Effective PatientProvider Communication, Adherence to Treatment and Self Management of Chronic Diseases In Underserved Populations (R01) Apply for PA 11 330 Funding Number: PA 11 330 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| mHealth Tools to Promote Effective PatientProvider Communication, Adherence to Treatment and Self Management of Chronic Diseases In Underserved Populations (R21) Apply for PA 11 332 Funding Number: PA 11 332 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Scholars Training for the Advancement of Research (STAR) Competitive Revision to NINR T32 Training Grants (T32) Apply for RFA NR 11 011 Funding Number: RFA NR 11 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of novel and emerging technologies for the accurate detection and diagnosis of polymicrobial infections in biomedical laboratory animal models (SBIR R43/R44) Apply for PA 11 340 Funding Number: PA 11 340 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of Novel and Emerging Technologies for the Accurate Detection and Diagnosis of Polymicrobial Infections in Biomedical Laboratory Animal Models (STTR R41/R42) Apply for PA 11 341 Funding Number: PA 11 341 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Research Network a Research Resource within Health Care Delivery System (Limited Competition U24) Apply for RFA CA 11 502 Funding Number: RFA CA 11 502 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 12 010", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.